These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30850328)

  • 1. Tapering of SSRI treatment to mitigate withdrawal symptoms.
    Horowitz MA; Taylor D
    Lancet Psychiatry; 2019 Jun; 6(6):538-546. PubMed ID: 30850328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation.
    van Geffen EC; Hugtenburg JG; Heerdink ER; van Hulten RP; Egberts AC
    Eur J Clin Pharmacol; 2005 Jun; 61(4):303-7. PubMed ID: 15906018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Discontinuation of SSRIs and SNRIs].
    Ruhe HG; Horikx A; van Avendonk MJP; Groeneweg BF; Mulder H; Woutersen-Koch H
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32186829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtherapeutic doses of SSRI antidepressants demonstrate considerable serotonin transporter occupancy: implications for tapering SSRIs.
    Shapiro BB
    Psychopharmacology (Berl); 2018 Sep; 235(9):2779-2781. PubMed ID: 30097698
    [No Abstract]   [Full Text] [Related]  

  • 6. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
    Meyer JH; Wilson AA; Sagrati S; Hussey D; Carella A; Potter WZ; Ginovart N; Spencer EP; Cheok A; Houle S
    Am J Psychiatry; 2004 May; 161(5):826-35. PubMed ID: 15121647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the dose-response curves of SSRIs.
    Preskorn SH
    J Psychiatr Pract; 2012 Jan; 18(1):38-45. PubMed ID: 22261982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography.
    Voineskos AN; Wilson AA; Boovariwala A; Sagrati S; Houle S; Rusjan P; Sokolov S; Spencer EP; Ginovart N; Meyer JH
    Psychopharmacology (Berl); 2007 Sep; 193(4):539-45. PubMed ID: 17497139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events after the abrupt discontinuation of paroxetine.
    Dominguez RA; Goodnick PJ
    Pharmacotherapy; 1995; 15(6):778-80. PubMed ID: 8602387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective serotonin reuptake inhibitor discontinuation syndrome: a review.
    Tamam L; Ozpoyraz N
    Adv Ther; 2002; 19(1):17-26. PubMed ID: 12008858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of Semistructured Interview and Scales to Assess Withdrawal Syndromes With Dose Reduction or Discontinuation of Selective Serotonin Reuptake Inhibitors or Serotonin Norepinephrine Reuptake Inhibitors.
    Cosci F; Romanazzo S; Mansueto G; Rontani P; Levitan MN; Halkjœr-Lassen RD; Quagliato LA; Nakamura T; Uematsu K; Nardi AE; Oe M; Chouinard VA; Chouinard G
    J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):17-22. PubMed ID: 34928557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.
    Finnema SJ; Halldin C; Bang-Andersen B; Bundgaard C; Farde L
    Psychopharmacology (Berl); 2015 Nov; 232(21-22):4159-67. PubMed ID: 25980484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder.
    Lundberg J; Tiger M; Landén M; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2012 Sep; 15(8):1167-72. PubMed ID: 22243688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin reuptake inhibitor withdrawal.
    Coupland NJ; Bell CJ; Potokar JP
    J Clin Psychopharmacol; 1996 Oct; 16(5):356-62. PubMed ID: 8889907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.
    Klein N; Sacher J; Geiss-Granadia T; Attarbaschi T; Mossaheb N; Lanzenberger R; Pötzi C; Holik A; Spindelegger C; Asenbaum S; Dudczak R; Tauscher J; Kasper S
    Psychopharmacology (Berl); 2006 Oct; 188(3):263-72. PubMed ID: 16955282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) – New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability.
    Cosci F; Chouinard G; Chouinard VA; Fava GA
    Riv Psichiatr; 2018; 53(2):95-99. PubMed ID: 29674777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Severe withdrawal symptoms with fever during paroxetine tapering off].
    Peeters FP; Zandbergen J
    Ned Tijdschr Geneeskd; 1999 Jul; 143(27):1429-31. PubMed ID: 10422558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective serotonin reuptake inhibitor. Discontinuation syndrome.
    Finfgeld DL
    J Psychosoc Nurs Ment Health Serv; 2002 Dec; 40(12):14-8. PubMed ID: 12491870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delirium Associated With Fluoxetine Discontinuation: A Case Report.
    Fan KY; Liu HC
    Clin Neuropharmacol; 2017; 40(3):152-153. PubMed ID: 28452902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Discontinuation syndrome after SSRI antidepressants].
    Lykkegaard LA; Videbech P
    Ugeskr Laeger; 2014 Feb; 176(3):231-5. PubMed ID: 24629750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.